Tofacitinib Versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
We found that the persistence and tolerability of vedolizumab were superior to tofacitinib in bio-naive UC, although the rates of clinical and biomarker remission were comparable. These data may help inform the positioning of advanced therapy.
Authors
- Nathan Constantine‐Cooke (ORCID: https://orcid.org/0000-0002-4437-8713)
- Nikolas Plevris (ORCID: https://orcid.org/0000-0002-3229-8759)
- Gareth‐Rhys Jones (ORCID: https://orcid.org/0000-0001-7355-2357)
- Claire O’Hare
- Alexander T. Elford (ORCID: https://orcid.org/0000-0001-6144-1369)
- Beatriz Gros (ORCID: https://orcid.org/0000-0002-5628-313X)
- Ian D. Arnott (ORCID: https://orcid.org/0000-0003-3352-9253)
- Charlie W. Lees (ORCID: https://orcid.org/0000-0002-0732-8215)
- Colin Noble
- J D Kennedy (ORCID: https://orcid.org/0000-0003-3860-3977)
Institutions
- The University of Melbourne (AU)
- Western General Hospital (GB)
- Edinburgh Cancer Research (GB)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Centre for Inflammation Research (GB)
- Institute of Genetics and Cancer (GB)
- Medical Research Network (US)
- The Queen's Medical Research Institute (GB)
- Cordoba University (US)
- University of Edinburgh (GB)
Publication Details
- Journal
- Journal of Crohn s and Colitis
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1093/ecco-jcc/jjae188
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.10
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Wellcome Trust
- UK Research and Innovation
- Australian Government
- Vifor Pharma